### Thursday, April 20, 2017

**10:00**  Arrivals and registration

**14:00-17:30**  Pre congress educational workshop: Multicriteria decision analysis (MCDA): from theory to practice in supporting evidence based policy decisions in healthcare.

**Faculty:** Z.Kalo (HU), D.Vitezic (HR), V.Zah (SRB), D.Atanasijevic (SRB), S.Bolanca (HR)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-14:05</td>
<td>Welcome &amp; introduction (D.Vitezic)</td>
</tr>
<tr>
<td>14:05-14:45</td>
<td>Is there a need for MCDA and why? (Z.Kalo)</td>
</tr>
<tr>
<td>14:45-15:10</td>
<td>MCDA from the perspective of researches, prescribers and patients (D.Vitezic)</td>
</tr>
<tr>
<td>15:10-15:30</td>
<td>MCDA from the perspective of payers and pharmaceutical industry (S.Bolanca)</td>
</tr>
<tr>
<td>15:30-15:45</td>
<td>Coffee break</td>
</tr>
<tr>
<td>15:45-17:30</td>
<td>MCDA tool - demonstration of use in oncology and rare diseases (V.Zah, D.Atanasijevic)</td>
</tr>
</tbody>
</table>

### Welcome session and opening ceremony

**18:00**  Welcome addresses by Congress Presidents and Auspices

**18:30**  Key note speech (Ken Paterson, UK): Our World 2017 - Looking Backwards, Looking Forwards?

**19:00**  Welcome reception
Friday, April 21, 2017

8:30 - 10:45  Plenary session 1: Pharmacoeconomics and outcomes research of novel cardiovascular medicines

Chairmen: Dinko Vitezic, Viktorija Erdeljic Turk

8:30  Davor Milicic (HR): CURRENT STATE OF CARDIOLOGY OUTCOMES IN CROATIA
8:55  Tabassome Simon (FR): LONG-TERM OUTCOME WITH ORAL ANTICOAGULANTS WITH OR WITHOUT DUAL ANTIPLATELET THERAPY AFTER AMI
9:20  Andrej Janzic (SI): THE IMPORTANCE OF MODEL VARIABILITY IN COST-EFFECTIVENESS ANALYSIS
9:40  Livio Garattini (IT): CHOLESTEROL-LOWERING DRUGS: SCIENCE AND MARKETING
10:05 Marta Kucan (HR): HYPOLIPEMICS USAGE IN CROATIA
10:20 Aleksandar Knezevic (HR): PHARMACOECONOMIC ASPECTS OF THE NEW PCSK-9i CLASS

10:45 Coffee break

11:00 - 13:00 Research communications 1

Chairmen: Jurij Furst, Carmen Hadjic Kostrencic

11:00  Rok Hren (SI): IMPACT OF POOR ADHERENCE ON COST-EFFECTIVENESS OF ADALIMUMAB IN THE TREATMENT OF PSORIASIS (PSO) AND PSORIATIC ARTHRITIS (PSA) IN SLOVENIA
11:25 Teotónio Albuquerque (PT): PATIENT SUPPORT PROGRAMS IMPACT ON HEALTH CARE BY INCREASING ADHERENCE, CLINICAL, HUMANISTIC AND ECONOMIC PATIENT OUTCOMES
11:50 Diana Mance (HR): RATIONAL DECISION MAKING IN THE ALLOCATION OF EXTREMELY EXPENSIVE DRUGS
12:05 Bertalan Nemeth (HU): APPLICATION OF MULTICRITERIA DECISION ANALYSIS (MCDA) TO FACILITATE EVIDENCE BASED HEALTH POLICY DECISIONS
12:30  Slobodanka Bolanca (HR): UTILISATION OF ANTICANCER DRUGS IN SOUTH EAST EUROPE: HOW CLOSE IS IT TO A STRATEGIC INVESTMENT IN HEALTH OUTCOMES?
12:45  Dragan Korolija Marinic (HR): GOVERNMENT WILLINGNESS TO PAY FOR CANCER TREATMENT IN CROATIA

13:00  Lunch break

14:00 - 16:30  Plenary session 2: Pricing policies and financing strategies for improving patient access to innovation

Chairmen: Igor Francetic, Slobodanka Bolanca

14:00  Stanislav Primozic (SI): REGULATORY APPROACHES FOR EARLY ACCESS OF MEDICINES IN EU
14:25  Zoltan Kalo (HU): METHODS FOR PHARMACEUTICAL PRICING
14:50  Andras Inotai (HU): RETHINKING BIOSIMILAR DRUG POLICIES
15:15  François Lamérant (B): LONG-TERM SUSTAINABILITY OF HEALTHCARE AND FINANCING OF INNOVATION
15:40  Jurij Fürst (SI): NEW IDEAS FOR IMPROVING ACCESS TO MEDICINES
16:05  Livio Garattini (IT): REIMBURSABLE DRUG CLASSES AND CEILINGS IN ITALY: WHY NOT ONLY ONE?

16:30  Coffee break

16:45-18:15 PLENARY DEBATE AND ROUNDTABLE DISCUSSION 1

HOW TO MANAGE & AFFORD ACCESS TO MEDICAL INNOVATION? ARE WE ANY CLOSER TO FINDING REASONABLE, PATIENT CENTRIC SOLUTION?

Moderator: Zoltan Kalo (HU)
Participants: B. Cukanovic (SRB), J. Furst (SI), L. Garattini (IT), M. Kucan (HR), F. Lamerant (B), R. Likic (HR), V. Sazonov (SI), Lj. Suturkova (MK)

20:30  CONGRESS NETWORKING DINNER
Saturday, April 22, 2017

8:30 - 10:45  Research communications 2

Chairmen: Ljubica Suturkova, Aleksandara Knezevic

8:30  Ines Potocnjak (HR): A RETROSPECTIVE, OBSERVATIONAL, COMPARATIVE AND PHARMACOECONOMIC STUDY OF BENZODIAZEPINE DERIVATIVES UTILIZATION FROM 2014 TO 2015 BETWEEN CROATIA AND SWEDEN

8:45  Iva Kraljickovic (HR): FEASIBILITY OF IMPLEMENTATION OF COLOUR-GRADED PICTOGRAMS ON MEDICAL PACKAGING REGARDING THE DRUGS’ IMPACT ON ABILITY TO DRIVE MOTOR VEHICLES

9:00  Stevce Acevski (MK): COST OF ILLNESS – ANTIBIOTIC TREATMENT OF NOSOCOMIAL INFECTIONS FROM METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS, ACCINETOBACTER SP. OR PSEUDOMONAS AERUGINOSA

9:20  August Cesarec (HR): BUDGET IMPACT ANALYSIS OF BIOSIMILAR TRASTUZUMAB FOR THE TREATMENT OF BREAST CANCER IN CROATIA

9:40  Aleksandra Kapedanovska Nestorovska (MK): COST-EFFECTIVENESS ANALYSIS OF OBINUTUZUMAB AS FIRST LINE TREATMENT OPTION FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN REPUBLIC OF MACEDONIA

10:00  Robert Likic (HR): BUDGET IMPACT ANALYSIS OF BIOSIMILAR RITUXIMAB FOR THE TREATMENT OF PATIENTS WITH MALIGNANCIES STEMMING FROM B LYMPHOCYTES IN CROATIA

10:20  Zorica Naumovska (MK): PHARMACOECONOMIC EVALUATION OF SORAFENIB AS FIRST-LINE TREATMENT FOR ADVANCED HEPATOCELLULAR CARCINOMA

10:45  Coffee break

11:00 - 13:00  Research communications 3

Chairmen: Dragana Atanasijevic, Rok Hren

11:00  Samir Mukinovic (BIH): THE ACCOUNTING CONCEPT IN FUNCTION OF RESTRICTIONS ON RIGHTS OF COMPULSORY HEALTH INSURANCE
11:20 Davor Mance (HR): **FOUR DEGREES OF PRICE DISCRIMINATION: EXAMPLES FROM PHARMACOECONOMICS**

11:40 Katerina Kopeckova (CZ): **COST OF ILLNESS FOR RENAL CELL CARCINOMA IN CZECH REPUBLIC**

12:00 Tanja Novakovic (SRB): **THE VALUE OF INNOVATION IN DECISION MAKING**

12:20 Viktorija Erdeljic Turk (HR): **USING SURROGATE EFFICACY ENDPOINTS IN EVALUATING BENEFITS AND COSTS OF ANTICANCER DRUGS IN METASTATIC DISEASE**

12:40 Luka Voncina (HR): **HEALTH TECHNOLOGY ASSESSMENT AS A BASIS FOR REIMBURSEMENT DECISIONS IN SOUTH EAST EUROPE: FROM LEGISLATION TO PRACTICE**

**13:00 Lunch break**

**14:00 - 16:30 Plenary session 3: Reimbursement evaluation and technology assessment of innovative medicines**

Chairmen: Livio Garattini, Diana Mance

14:00 Thomas Griesbacher (A): **EVALUATION OF THERAPEUTIC BENEFIT AS BASIS FOR REIMBURSEMENT BY THE NATIONAL SOCIAL INSURANCE INSTITUTIONS IN AUSTRIA**

14:25 Rok Hren (SI): **A REVIEW OF VALUE-BASED PRICING OF ONCOLOGICAL DRUGS**

14:50 Dragana Atanasijevic (SRB): **IMPLEMENTATION OF MANAGED ENTRY AGREEMENTS IN SERBIA**

15:15 Maria Kamusheva (BG): **APPLICATION OF NEW HTA LEGISLATION IN BULGARIA**

15:40 Mirjana Huic (HR): **HTA IN CROATIA: WHY IS INTERNATIONAL COLLABORATION SO IMPORTANT?**

16:05 Ken Paterson (UK): **RAPID HEALTH TECHNOLOGY ASSESSMENT OF NEW MEDICINES (INCL. CANCER MEDICINES) - LESSONS FROM 15 YEARS EXPERIENCE IN SCOTLAND**

**16:30 Coffee break**
16:45-18:15  PLENARY DEBATE AND ROUNDTABLE DISCUSSION 2
CONSENZUS ON MINIMALLY ACCEPTABLE EVALUATION METHODS FOR NEW HEALTH TECHNOLOGIES TO ENSURE FAST & FAIR ACCESS TO PATIENTS
Moderator: Dinko Vitezic (HR)
Participants: D. Atanasijevic (SRB), V. Erdeljic Turk (HR), T. Griesbacher (A), R. Hren (SI), M. Huic (HR), K. Kopeckova (CZ), K. Paterson (UK), L. Voncina (HR)

Sunday, April 23, 2017

9:00  Joint meeting of national Pharmacoeconomic Associations:
HOW TO IMPROVE REGIONAL COLLABORATION AND RESEARCH IN THE FIELD OF PHARMACOECONOMICS AND OUTCOMES RESEARCH

10:30  Coffee break

11:00  Joint meeting of national Pharmacoeconomic Associations:
ORGANIZATION OF THE 8TH ADRIATIC CONGRESS OF PHARMACOECONOMICS AND OUTCOMES RESEARCH

12:30  Lunch & Departures